Evidence map›Paper›PMID 41191045›Full record

Trial reportPsychopharmacology2026

Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm.

Milad Soltanzadeh, Zheng Wang, Shona G Allohverdi, Colleen E Charlton, André Schmidt, Franz X Vollenweider, Andreea O Diaconescu

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Milad SoltanzadehInstitute of Medical Science, University of Toronto, 1 King's College Circle, Toronto, M5S 3K3, ON, Canada. milad.soltanzadeh@mail.utoronto.ca.ORCID http://orcid.org/0009-0006-7088-8924
Zheng WangKrembil Centre for Neuroinformatics, Centre for Addiction and Mental Health (CAMH), 250 College St., Toronto, M5T 1R8, ON, Canada.
Shona G AllohverdiInstitute of Medical Science, University of Toronto, 1 King's College Circle, Toronto, M5S 3K3, ON, Canada.
Colleen E CharltonKrembil Centre for Neuroinformatics, Centre for Addiction and Mental Health (CAMH), 250 College St., Toronto, M5T 1R8, ON, Canada.
André SchmidtDepartment of Clinical Research (DKF), University of Psychiatric Clinics (UPK), University of Basel, Wilhelm Klein-Strasse 27, Basel, 4002, Switzerland.
Franz X VollenweiderNeuropsychopharmacology and Brain Imaging Unit, University Hospital of Psychiatry, Lenggstrasse 31, Zurich, 8008, Switzerland.
Andreea O DiaconescuInstitute of Medical Science, University of Toronto, 1 King's College Circle, Toronto, M5S 3K3, ON, Canada.

Funding

Canadian Institute for Health Research (CIHR) 452559
6 · The paper itself

Abstract

rationaleKetamine and psilocybin have demonstrated therapeutic potential for mental disorders, including major depressive disorder, yet they engage distinct mechanisms of action. Ketamine, a dissociative hallucinogen, acts by blocking N-methyl-D-aspartate receptors (NMDAR), whereas psilocybin primarily targets serotonin receptors. These divergent mechanisms are reflected in their electrophysiological biomarkers.

objectivesThis study aimed to investigate the divergent effects of ketamine and psilocybin on different elements of the EEG frequency spectrum, focusing on aperiodic components as an indicator of excitation-inhibition balance in the neural circuitry.

methodsWe re-analyzed a previously acquired EEG dataset from healthy volunteers using a placebo-controlled within-subject crossover design (Schmidt et al., Neuropsychopharmacology 37(4):865-875 2012). Participants received either placebo or S-ketamine (N=19) and placebo or psilocybin (N=16) during an auditory roving paradigm. Spectral parameters including periodic and aperiodic were extracted and partial least squares analysis was employed.

resultsKetamine significantly altered the offset and slope of the EEG spectrum, suggesting a disruption in excitatory-inhibitory balance. While both drugs commonly reduced alpha power in similar regions, beta band activity was decreased exclusively under ketamine.

conclusionsThese findings highlight ketamine's unique effects on aperiodic EEG components, reinforcing its role as a neurochemical model of prodromal psychosis. Psilocybin's effects appear distinct, emphasizing its targeted influence on oscillatory activity.

Indexed as

ElectroencephalographyHallucinogensKetaminePsilocybinAdultCross-Over StudiesDouble-Blind MethodFemaleHumansMaleYoung AdultHallucinogensKetaminePsilocybin1/fAperiodic componentEEGKetaminePartial least squaresPsilocybinPsychedelics

Identifiers

PMID41191045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.